BUZZ-ADMA Biologics rises after rejecting short-seller's claims

ADMA Biologics, Inc.

ADMA Biologics, Inc.

ADMA

0.00

** Shares of biotech firm ADMA Biologics ADMA.O rise 12.44% to $9.32 premarket

** Co issues statement against a March 24 report by short seller Culper Research, rejecting what it called false and misleading claims about its business

** Says demand for Asceniv, its antibody treatment for immune-deficient patients, has been rising for more than two years and is now at a record high

** Says the amount of product held by distributors is normal for the industry and reflects the need to keep enough supply on hand because the drug takes a long time to make

** Adds it received clean audit opinions for 2024 and 2025 and there have never been any undisclosed related party transactions in violation of U.S. securities laws

** ADMA shares were up over 6% in 2025


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.